ChemPartner(SZ:300149) Xin Lang Cai Jing·2025-10-30 12:53Core Insights - RuiZhi Pharmaceutical is a leading pharmaceutical research and production outsourcing service provider in China, established on January 26, 2000, and listed on the Shenzhen Stock Exchange on December 22, 2010 [1] Financial Performance - For Q3 2025, RuiZhi Pharmaceutical reported revenue of 817 million yuan, ranking 13th among 29 companies in the industry. The top company, WuXi AppTec, had revenue of 32.857 billion yuan, while the industry average was 2.547 billion yuan [2] - The main business revenue from pharmaceutical research and production outsourcing services was 529 million yuan, accounting for 99.06% of total revenue. Other revenues included 2.7823 million yuan from prebiotic products (0.52%), 1.846 million yuan from rental income (0.35%), and 397,300 yuan from other sources (0.07%) [2] - The net profit for the same period was 7.1621 million yuan, ranking 23rd in the industry. The leading company, WuXi AppTec, reported a net profit of 12.206 billion yuan, with the industry average at 585 million yuan [2] Financial Ratios - As of Q3 2025, RuiZhi Pharmaceutical's debt-to-asset ratio was 35.77%, higher than the previous year's 35.56% and above the industry average of 22.79% [3] - The gross profit margin for the period was 27.55%, an increase from 19.22% in the previous year, but still below the industry average of 37.70% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.70% to 42,600, while the average number of circulating A-shares held per shareholder increased by 4.94% to 11,200 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fourth largest, holding 24.3258 million shares, a decrease of 6,100 shares from the previous period [5] Leadership Compensation - The chairman, Hu Ruilian, received a salary of 1.2011 million yuan in 2024. He holds multiple positions, including CEO and director of RuiZhi Pharmaceutical [4]